Analyst Ratings For NASDAQ:INO – Inovio Pharmaceuticals (NASDAQ:INO)
Today, Maxim Group reiterated its Buy rating on NASDAQ:INO – Inovio Pharmaceuticals (NASDAQ:INO) with a price target of $8.00.
Some recent analyst ratings include
- 5/21/2018-Maxim Group Reiterated Rating of Buy.
- 10/6/2017-Citigroup initiated coverage with a Buy rating.
- 7/18/2017-Aegis Reiterated Rating of Buy.
- 6/8/2017-Piper Jaffray Companies Upgrade from a “Neutral ➝ Overweight” rating to a “” rating.
- 5/25/2017-Stifel Nicolaus Reiterated Rating of Buy.
Recent Insider Trading Activity For NASDAQ:INO – Inovio Pharmaceuticals (NASDAQ:INO)
NASDAQ:INO – Inovio Pharmaceuticals (NASDAQ:INO) has insider ownership of 9.40% and institutional ownership of 32.82%.
- On 4/16/2018 David B Weiner, Director, sold 9,000 with an average share price of $4.91 per share and the total transaction amounting to $44,190.00.
- On 4/12/2018 Jong Joseph Kim, CEO, sold 103,750 with an average share price of $5.14 per share and the total transaction amounting to $533,275.00.
- On 4/12/2018 Simon X Benito, Director, sold 3,750 with an average share price of $5.23 per share and the total transaction amounting to $19,612.50.
- On 5/25/2017 David B Weiner, Director, sold 8,000 with an average share price of $8.00 per share and the total transaction amounting to $64,000.00.
- On 3/31/2017 Jong Joseph Kim, CEO, sold 147,180 with an average share price of $6.54 per share and the total transaction amounting to $962,557.20.
- On 3/27/2017 Morton Collins, Director, bought 21,300 with an average share price of $6.25 per share and the total transaction amounting to $133,125.00.
- On 8/29/2016 Niranjan Sardesai, COO, sold 21,800 with an average share price of $9.30 per share and the total transaction amounting to $202,740.00.
Recent Trading Activity for NASDAQ:INO – Inovio Pharmaceuticals (NASDAQ:INO)
Shares of NASDAQ:INO – Inovio Pharmaceuticals closed the previous trading session at 4.84 down -0.15 3.01% with shares trading hands.